## Aimee L Jackson

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/4208841/aimee-l-jackson-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

26 9,968 36 36 g-index h-index citations papers 11.6 36 10,714 5.7 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
36	Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth and. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1139-1149	12.9	35
35	A MicroRNA-29 Mimic (Remlarsen) Represses Extracellular Matrix Expression and Fibroplasia in the Skin. <i>Journal of Investigative Dermatology</i> , <b>2019</b> , 139, 1073-1081	4.3	80
34	Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. <i>British Journal of Haematology</i> , <b>2018</b> , 183, 428-444	4.5	129
33	Mechanisms of Oligonucleotide Actions <b>2018</b> , 1-37		
32	The Efficacy of Cardiac Anti-miR-208a Therapy Is Stress Dependent. <i>Molecular Therapy</i> , <b>2017</b> , 25, 694-70	<b>)4</b> 1.7	16
31	Safety assessment of food and feed from biotechnology-derived crops employing RNA-mediated gene regulation to achieve desired traits: a scientific review. <i>Regulatory Toxicology and Pharmacology</i> , <b>2013</b> , 66, 167-76	3.4	74
30	Reflections on microRNAs in chronic pulmonary disease: looking into the miR-ror and crystal ball. <i>Inflammation and Allergy: Drug Targets</i> , <b>2013</b> , 12, 88-98		3
29	A multiplexed siRNA screening strategy to identify genes in the PARP pathway. <i>Journal of Biomolecular Screening</i> , <b>2012</b> , 17, 1316-28		4
28	Gene expression profiling following NRF2 and KEAP1 siRNA knockdown in human lung fibroblasts identifies CCL11/Eotaxin-1 as a novel NRF2 regulated gene. <i>Respiratory Research</i> , <b>2012</b> , 13, 92	7.3	27
27	Developing microRNA therapeutics: approaching the unique complexities. <i>Nucleic Acid Therapeutics</i> , <b>2012</b> , 22, 213-25	4.8	49
26	Effect of Xpcl1 activation and p27(Kip1) loss on gene expression in murine lymphoma. <i>PLoS ONE</i> , <b>2011</b> , 6, e14758	3.7	5
25	Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. <i>Nature Reviews Drug Discovery</i> , <b>2010</b> , 9, 57-67	64.1	699
24	Hidden reach of the micromanagers. <i>BMC Biology</i> , <b>2010</b> , 8, 53	7.3	1
23	MicroRNA-like off-target transcript regulation by siRNAs is species specific. <i>Rna</i> , <b>2009</b> , 15, 308-15	5.8	64
22	Myc-regulated microRNAs attenuate embryonic stem cell differentiation. <i>EMBO Journal</i> , <b>2009</b> , 28, 3157	-79	159
21	MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. <i>Molecular and Cellular Biology</i> , <b>2008</b> , 28, 2167-74	4.8	480
20	Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. <i>Cancer Research</i> , <b>2008</b> , 68, 10105-12	10.1	292

## (1996-2008)

19	Chromosome 20q amplification regulates in vitro response to Kinesin-5 inhibitor. <i>Cancer Informatics</i> , <b>2008</b> , 6, 147-64	2.4	3	
18	Genome-scale RNAi profiling of cell division in human tissue culture cells. <i>Nature Cell Biology</i> , <b>2007</b> , 9, 1401-12	23.4	254	
17	Genome-wide resources of endoribonuclease-prepared short interfering RNAs for specific loss-of-function studies. <i>Nature Methods</i> , <b>2007</b> , 4, 337-44	21.6	151	
16	A microRNA component of the p53 tumour suppressor network. <i>Nature</i> , <b>2007</b> , 447, 1130-4	50.4	2264	
15	Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. <i>Molecular and Cellular Biology</i> , <b>2007</b> , 27, 2240-52	4.8	462	
14	Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. <i>Molecular and Cellular Biology</i> , <b>2006</b> , 26, 9377-86	4.8	159	
13	Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. <i>Rna</i> , <b>2006</b> , 12, 1197-205	5.8	593	
12	Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. <i>Rna</i> , <b>2006</b> , 12, 1179-87	5.8	681	
11	Minimizing the risk of reporting false positives in large-scale RNAi screens. <i>Nature Methods</i> , <b>2006</b> , 3, 77	7 <b>:9</b> 1.6	362	
10	How will RNAi facilitate drug development?. Science Signaling, 2005, 2005, pe39	8.8	11	
9	Noise amidst the silence: off-target effects of siRNAs?. <i>Trends in Genetics</i> , <b>2004</b> , 20, 521-4	8.5	298	
8	Expression profiling reveals off-target gene regulation by RNAi. <i>Nature Biotechnology</i> , <b>2003</b> , 21, 635-7	44.5	1857	
7	The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , <b>2001</b> , 477, 7-21	3.3	452	
6	Microsatellite instability induced by hydrogen peroxide in Escherichia coli. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , <b>2000</b> , 447, 187-98	3.3	41	
5	On the origin of multiple mutations in human cancers. Seminars in Cancer Biology, 1998, 8, 421-9	12.7	42	
4	Origin of multiple mutations in human cancers. <i>Drug Metabolism Reviews</i> , <b>1998</b> , 30, 285-304	7	7	
3	The mutation rate and cancer. <i>Genetics</i> , <b>1998</b> , 148, 1483-90	4	164	
2	OXIDANTS AND MULTIPLE MUTATIONS IN CANCER. <i>Biochemical Society Transactions</i> , <b>1996</b> , 24, 522S-52251			

Cdc7 protein kinase for DNA metabolism comes of age. *Molecular Microbiology*, **1994**, 11, 805-10

4.1 50